on ABSCIENCES (EPA:AB)
AB Science to Present Masitinib Update in Upcoming Webcast
AB Science SA has announced a live webcast scheduled for January 28, 2025. This event will run from 5.30pm to 6.45pm CET, aiming to provide insights into the masitinib platform. The webcast will feature prominent figures from the company, including co-founder and CEO Alain Moussy. Dr. Olivier Hermine, a distinguished hematologist from Necker-Enfants Malades Hospital in Paris, will also be present.
Masitinib, a key compound in AB Science's proprietary portfolio, is being developed for applications in various fields such as oncology and neurological diseases. Additionally, it holds registration for use in veterinary medicine.
The webcast will be accessible through ZOOM, providing both audio and presentation. This event aims to update stakeholders on the developments and prospects within AB Science's research.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABSCIENCES news